ATNM:NYE-Actinium Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 8.56

Change

-0.35 (-3.93)%

Market Cap

USD 0.12B

Volume

0.18M

Average Target Price

USD 3.00 (-64.95%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.

Company Website : http://www.actiniumpharma.com

Address : 275 Madison Avenue, New York, NY, United States, 10016

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.49

52 Week High : 12.75

Short Ratio : 0.90

52 Week Low : 0.16

Shorted Shares : 637,973

200 Day Moving Average : 8.92

Shorted Shares Previous Month : 451,384

50 Day Moving Average : 9.57

Shares Held By Insiders : 9.02%

Short Percentage : 5.00%

Shares Held by Institutions : 13.9%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-1.13 (-1.63%)

 USD161.61B 24.87 2.76
ADPT Adaptive Biotechnologies Corpo..

-2.39 (-4.96%)

 USD6.55B 38.68 N/A
BHVN Biohaven Pharmaceutical Holdin..

-1.08 (-1.71%)

 USD3.65B N/A N/A
ADCT ADC Therapeutics SA

-0.66 (-1.93%)

 USD2.54B -99,999.99 N/A
ZYME Zymeworks Inc

+0.49 (+1.13%)

 USD1.98B 300.20 N/A
MYOV Myovant Sciences Ltd

-2.32 (-10.63%)

 USD1.97B N/A N/A
RCUS Arcus Biosciences, Inc

-0.01 (-0.06%)

 USD1.15B N/A N/A
KDMN Kadmon Holdings, Inc

-0.06 (-1.56%)

 USD0.66B 2.20 N/A
CVM CEL-SCI Corporation

-0.33 (-2.58%)

 USD0.48B N/A N/A
PFNX Pfenex Inc

-0.02 (-0.16%)

 USD0.44B 268.67 63.90

ETFs Containing ATNM

Symbol Name Weight Mer Price(Change) Market Cap
RJZ ELEMENTS Linked to the Ro.. 0.00 % 0.75 %

+0.04 (+0.43%)

 USD3.76M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.89% 72% C- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.89% 72% C- 93% A
Trailing 12 Months  
Capital Gain 22.99% 54% F 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.99% 54% F 87% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.90% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.90% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.35% N/A N/A N/A N/A
Risk Adjusted Return 37.15% N/A N/A N/A N/A
Market Capitalization 0.12B 47% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.56 73% C 31% F
Price / Cash Flow Ratio -5.53 41% F 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -64.68% 63% D 7% F
Return on Invested Capital -292.59% 16% F 0% N/A
Return on Assets -34.77% 42% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.90 69% D+ 70% C-
Short Percent 4.70% 55% F 51% F
Beta 1.49 50% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.